clinical trial · NCT06798519
Relative Bioavailability Study of HNC364 Injectable Suspension
Guangzhou Henovcom Bioscience Co. Ltd.·phase1·active not recruiting·n = 30
Parkinson's Disease (PD)HNC364 Injectable SuspensionRasagiline Tablets
brief summary
HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration. This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECT® (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy adult subjects.
started
May 8, 2026
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Jun 2, 2026
official title
A Relative Bioavailability Study of HNC364 Following Intramuscular Injections vs. AZILECT® (Rasagiline Tablet) Following Oral Administration at the Steady-State in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol